Protara Therapeutics (NASDAQ:TARA – Get Free Report) posted its earnings results on Friday. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.02, FiscalAI reports.
Protara Therapeutics Price Performance
Shares of NASDAQ:TARA traded up $0.17 during trading on Friday, reaching $2.30. The stock had a trading volume of 690,546 shares, compared to its average volume of 1,023,812. Protara Therapeutics has a 52 week low of $2.09 and a 52 week high of $7.82. The business’s 50-day moving average price is $3.03 and its 200 day moving average price is $4.49. The stock has a market capitalization of $135.93 million, a PE ratio of -1.70 and a beta of 1.54.
Analyst Upgrades and Downgrades
TARA has been the topic of a number of analyst reports. Wall Street Zen upgraded Protara Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 5th. Cantor Fitzgerald reissued an “overweight” rating on shares of Protara Therapeutics in a report on Thursday, October 15th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Protara Therapeutics in a research note on Thursday, October 15th. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Protara Therapeutics has an average rating of “Moderate Buy” and an average price target of $26.25.
Read Our Latest Stock Analysis on TARA
About Protara Therapeutics
Protara Therapeutics, Inc is a clinical-stage biotechnology company focused on developing transformative therapies for cancer and other serious diseases. The company’s lead product candidate, TARA-002, is an investigational cell-based immunotherapy derived from a proprietary preparation of Streptococcus pyogenes. Protara is evaluating TARA-002 primarily for the treatment of non-muscle-invasive bladder cancer.
Protara has also investigated TARA-002 for lymphatic malformations, rare abnormalities of the lymphatic system that can cause swelling, pain and other complications.
Featured Stories
- Five stocks we like better than Protara Therapeutics
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Protara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
